DX3-213B

Key Product Details

Product Description

DX3-213B is a potent oxidative phosphorylation (OXPHOS) complex I (also known as NDUFS7) antagonist (IC₅₀ = 3.6 nM). DX3-213B impairs ATP generation (IC₅₀ = 11 nM) and inhibits the proliferation of MIA PaCa-2 cells (IC₅₀ = 9 nM) in galactose-containing media. In vivo, DX3-213B significantly delays tumor growth in a syngeneic mouse model of pancreatic cancer. DX3-213B is orally bioavailable.

Licensing Information

Sold under license from the University of Michigan

Product Specifications for DX3-213B

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for DX3-213B

The following data is based on the product molecular weight 478.57.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.18 mL	20.90 mL	41.79 mL
2.5 mM	0.84 mL	4.18 mL	8.36 mL
5 mM	0.42 mL	2.09 mL	4.18 mL
25 mM	0.08 mL	0.42 mL	0.84 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Xue Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancer. J.Med.Chem. 2022 PMID: 35167303
• Xu First-in-class NADH/Ubiquinone oxidoreductase core subunit S7 (NDUFS7) antagonist for the treatment of pancreatic cancer. ACS Pharmacol.Transl.Sci. 2023 PMID: 37588763

Product Documents for DX3-213B